Featured Post from ChristianaCare

ChristianaCare and The Wistar Institute advance partnership with new cancer research strategies

Mar 16, 2022

4 min

ChristianaCare’s Helen F. Graham Cancer Center & Research Institute is advancing its historic partnership with the Ellen and Ronald Caplan Cancer Center of The Wistar Institute in Philadelphia with three new research projects under way.


The new research projects consist of a population health study targeting triple negative breast cancer. Other projects focus on a new therapeutic target for epithelial ovarian cancer, the most lethal gynecologic cancer in the developed world, and the development of “mini organs” derived from stem cells.


Targeting triple negative breast cancer

Delaware has one of the highest incidence rates of triple-negative breast cancer in the United States. This highly aggressive cancer has few treatment options, because the cells test negative for three known treatment targets – estrogen, progesterone and HER2 protein receptors.


Working with patient data from the Graham Cancer Center, researchers are investigating potential contributing factors such as diet, alcohol use and genetic variants among women, and the effects of these on cancer metabolism. The team will also examine spatial relationships between cancer “hot spots”—geographic areas with a higher-than-expected prevalence—and modifiable risk factors.


Key resources for the study are blood and tissue samples from the Graham Cancer Center’s Tissue Procurement Center and its statewide High-Risk Family Cancer Registry.


The research team will be led by Director of Population Health Research at ChristianaCare Scott Siegel, Ph.D., and Lead Research Scientist Jennifer Sims Mourtada, Ph.D., at the Graham Cancer Center’s Cawley Center for Translational Cancer Research (CTCR). They will join Zachary Schug, Ph.D., at Wistar’s Molecular and Cellular Oncogenesis Program.


Researching novel therapy for ovarian cancer

The latest study supported by the Graham Cancer Center’s Tissue Procurement Program targets KAT6A expression as a novel therapy for ovarian cancer caused by a specific genetic mutation, called PP2R1A.


Epithelial ovarian cancer is the most common form of ovarian cancer and the leading cause of gynecologic cancer deaths in the United States. Chemoresistance to currently available platinum-based drugs like cisplatin represents a major treatment challenge, as more than 50 percent of affected women ultimately relapse and die from this disease.


Wistar’s Rugang Zhang, Ph.D., leader of the Immunology, Microenvironment and Metastases Program, is focused on developing novel therapeutics for subtypes of ovarian cancer that currently have no effective therapies and on improving the current standard of care. Dr. Zhang’s previous work suggests that KAT6A signaling plays a critical role in ovarian cancer progression. Targeting this signaling pathway could be an effective strategy for treating ovarian cancer.


Working with Dr. Zhang on this project are Graham Cancer Center gynecologic oncologists Mark Cadungog, M.D., director of Robotic Surgery, and Sudeshna Chatterjee-Paer, M.D., and Cawley CTCR’s Stephanie Jean, M.D., director of Gynecologic Oncology Research. Also collaborating with the team is Wistar’s Alessandro Gardini, Ph.D., assistant professor in the Gene Expression & Regulation Program.


‘Mini organs’ offer hope for therapeutics

Dr. Sims-Mourtada at the Cawley CTCR will lead a new program to culture organ-specific tissue from stem cells that could change the way diseases are studied and treated.


These so called “mini organs” or “organoids” are three-dimensional tissue cultures grown in the lab that replicate the complexity and functions of a specific tissue or organ found in the body. Organoids offer scientists a better model for how drugs and other therapeutics might interact with a patient’s particular type of tumor, opening new avenues for precision medicine.


“The ability to grow each patient’s tumor in a three-dimensional organoid along with our capability to create patient-derived xenograft or animal models as part of our PDX core, will allow us to fully capture the effects of genetic as well as gene altering behavioral and environmental influences that are lacking in current research models,” said Dr. Sims-Mourtada. “Our collaboration with Wistar to build these programs raises our clinical platform to the next level for studying new cancer biomarkers and treatments.”


Advancing a Pioneering Partnership

The Graham Cancer Center made history when it signed a first-of-its-kind agreement in 2011 with The Wistar Institute, pairing a National Cancer Institute, NCI-designated basic research institution with a community cancer center that is also an NCI Community Oncology Research Program (NCORP).


“Our partnership with Wistar has attracted national recognition as a model of collaboration that leverages cutting-edge research to benefit cancer prevention and therapy statewide,” says Nicholas J. Petrelli, M.D., Bank of America endowed medical director of ChristianaCare’s Helen F. Graham Cancer Center and Research Institute. “With Wistar, our productive collaborations over the last decade continue to drive discovery research toward clinical trials to benefit patients here at the Graham Cancer Center and in communities everywhere.”


“The Graham Center has been an ideal partner in our mission,” said Dario C. Altieri, M.D., Wistar president and CEO and director of the Ellen and Ronald Caplan Cancer Center. “Our scientists at Wistar have access to clinically-annotated primary patient specimens of the highest quality. As the majority of patients at the Graham Cancer Center are treatment naïve, this collaboration affords an opportunity to conduct unique, high impact mechanistic and correlative studies that will ultimately advance important scientific discoveries that hopefully will lead to better cancer therapies.”

You might also like...

Check out some other posts from ChristianaCare

2 min

Maureen Leffler, D.O., Named ChristianaCare’s Chief Wellbeing Officer

Maureen “Mo” Leffler, D.O., MPH, has been appointed chief wellbeing officer of ChristianaCare, effective Nov. 25. In her role, Leffler leads the ChristianaCare Center for WorkLife Wellbeing and strategies to enhance the professional fulfillment and well-being of ChristianaCare’s nearly 14,000 caregivers, overseeing advocacy programs and initiatives to optimize their experience and foster a culture of well-being throughout the organization. She works closely with leaders across key departments to address factors impacting caregiver well-being. Leffler most recently served as the inaugural chief wellbeing officer at Nemours Children’s Health, where she helped the organization to achieve the 2022 Joy in Medicine distinction from the American Medical Association for prioritizing proven efforts to enhance the professional fulfillment of physicians. There, she established a Center for Associate Wellbeing; led the first systemwide assessment to strategically address well-being and burnout; and implemented a peer support program and expanded the scope of resources available to support the emotional and mental health needs of employees. In collaboration with organizational leaders, she supported targeted clinical team assessments and systems-based interventions to foster well-being. Prior to this role, Leffler served as a pediatric rheumatologist at Nemours and as an assistant professor of pediatrics in the Division of Rheumatology at Thomas Jefferson University. Since 2017, Leffler has served as the course director of the Chief Resident Leadership Training Program for the Accreditation Council for Graduate Medical Education (ACGME). In response to the COVID-19 outbreak, she co-chaired ACGME’s National Task Force on Well-Being. She and her team developed a national graduate medical education well-being community, which she continues to convene, to understand the evolving challenges and share strategies to improve well-being. She represents the ACGME as a coach for the National Academy of Medicine Action Collaborative on Clinical Well-Being and Resilience. She also serves as a consultant to the Professional Satisfaction team at the American Medical Association. Leffler earned her medical degree from the Philadelphia College of Osteopathic Medicine, followed by a residency in pediatrics at Nemours and Thomas Jefferson University Hospital, where she served as chief resident. She subsequently trained in pediatric rheumatology at Nemours and Jefferson. She also earned a Master of Public Health from Temple University and studied chemistry at St. Joseph’s University. Recently, Leffler completed the Georgetown Executive Leadership Certification Program.

2 min

ChristianaCare Will Establish New Health Care Campus in Aston, Delaware County, Pennsylvania

ChristianaCare has announced that Aston, PA will be the location for its next health care campus that will feature a neighborhood hospital and a health center. This is one of two facilities that ChristianaCare plans to open in Delaware County, as announced in February 2024. The hospital will be built in partnership with Emerus Holdings, Inc., the nation’s leading developer of neighborhood hospitals. The ChristianaCare Aston Campus, located at 700 Turner Industrial Way, is expected to open in the second half of 2026. The site was chosen based on a market assessment of historical and projected demographic data and health care service availability as well as a consumer survey, community input and feedback from elected officials and business leaders. The study identified gaps in health care accessibility, concluding that Aston would be an ideal location for a health campus. “We are thrilled to be bringing high quality health care services to our neighbors in Aston in Delaware County,” said Jennifer Schwartz, chief strategy officer at ChristianaCare. “Our goal is to make access to health care easy, convenient and close to home in a way that is sustainable and right-sized to meet the needs of the local community.” The neighborhood hospital will operate 24/7 with approximately 10 inpatient beds and an emergency department. The emergency department will treat common emergency care needs such as falls, injuries, heart attacks and strokes. The hospital will also provide diagnostic capabilities, including ultrasound, computed tomography (CT), X-ray and laboratory services. In addition to on-site staff, the hospital will benefit from access to virtual consults — such as neurology and cardiology — to support safe and effective care. ChristianaCare will add a health center on the second floor of the hospital offering outpatient services. These services will be developed based on community needs and are expected to include primary and specialty care practices plus an array of other clinical services. The announcement comes as construction is already under way on ChristianaCare’s first Pennsylvania neighborhood hospital, in West Grove, nearby in southern Chester County, which is projected to open mid-2025. Together, these three new campuses represent a new layer of care coming to southeastern Pennsylvania. ChristianaCare has been providing health care services to the residents of southeastern Pennsylvania for many years. Today, ChristianaCare offers primary care in three Chester County practices that are located in Jennersville, West Grove and Kennett Square. In addition, Concord Health Center in Chadds Ford, Delaware County, provides a wide array of services, including primary care, women’s health, sports medicine, behavioral health and more. Combined, ChristianaCare is now the medical home for 25,000 residents in these communities.

2 min

Kert Anzilotti, M.D., Appointed President of the Medical Group of ChristianaCare

Kert Anzilotti, M.D., MBA, FACR has been appointed president of the Medical Group of ChristianaCare. Anzilotti has served as interim president since June 2024. He will also continue in his role as system chief medical officer of ChristianaCare. As president of the ChristianaCare Medical Group, Anzilotti will seek to improve every aspect of care for every person the Medical Group touches. He will focus on the optimization of care delivery, strategic visioning, network development, clinical technology implementation and leveraging medical informatics. Anzilotti will continue to develop new care models that transcend settings, promote value-based care and improve the patient experience across the clinical enterprise. Among his priorities are the adoption of population health measures, the embedding of health equity into care delivery and workforce development, further expansion of access points for patients and the continuous enhancement of patient and caregiver experience. “Dr. Anzilotti is exceptionally qualified to lead the Medical Group of ChristianaCare,” said Janice E. Nevin, M.D., MPH, president and CEO of ChristianaCare. “His passion for our mission and vision for the future strength of our Medical Group is unwavering. Since joining ChristianaCare in 2011, Dr. Anzilotti has earned a well-deserved reputation as a thoughtful and collaborative leader.” Anzilotti has served in numerous leadership roles at ChristianaCare, including as chief medical officer, acute care; chair of the Department of Radiology; medical director of Imaging Services; and physician leader of the Neurosciences Service Line. He also previously served as Interim President and CEO for the eBrightHealth ACO with responsibility for physician leadership and network operations. He is board certified in Neuroradiology. “Over the many years I have been at ChristianaCare, I have had the privilege of witnessing the dedication and compassion of my Medical Group colleagues as we served together with love and excellence,” Anzilotti said. “I am honored to lead this incredible, dynamic group that is reshaping the future of care, ensuring everyone we serve can achieve their best health.” Anzilotti earned his medical degree from Jefferson Medical College of Thomas Jefferson University in Philadelphia. He earned his MBA at the University of Delaware, completed the Managing Health Care Delivery Course at Harvard Business School and graduated as Physician Executive Fellow in the Health Management Academy, GE Fellows Program. The Medical Group of ChristianaCare consists of over 2,200 dedicated doctors, nurse practitioners, physician assistants and other caregivers. This highly skilled team delivers exceptional care through ChristianaCare’s community-based primary care and specialty care practices serving Delaware and surrounding states. Additionally, the Medical Group collaborates with ChristianaCare hospitalists to ensure seamless continuity of care for our patients, from primary care to hospital care and back again.

View all posts
Powered by